Scientists from the German Cancer Research Center (DKFZ) and the stem cell institute HI-STEM* in Heidelberg have succeeded for the first time in directly reprogramming human blood cells into a previously unknown type of neural stem cell.
These induced stem cells are similar to those that occur during the early embryonic development of the central nervous system. They can be modified and multiplied indefinitely in the culture dish and can represent an important basis for the development of regenerative therapies.
Stem cells are considered to be the all-rounders of our tissues: they can multiply indefinitely and then – if they are pluripotent embryonic stem cells – generate all conceivable cell types. In 2006, the Japanese scientist Shinya Yamanaka recognized that such cells could also be produced in the laboratory – from mature body cells. Four genetic factors alone are sufficient to reverse the course of development and produce so-called induced pluripotent stem cells (iPS) that have identical properties to embryonic stem cells. Yamanaka was awarded the Nobel Prize for Medicine in 2012 for this discovery.
“This was a major breakthrough for stem cell research,” said Andreas Trumpp, German Cancer Research Center (DKFZ) and Director of HI-STEM in Heidelberg. “This applies in particular to for research in Germany, where the generation of human embryonic stem cells is not permitted. Stem cells have enormous potential both for basic research and for the development of regenerative therapies that aim to restore diseased tissue in patients. However, reprogramming is also associated with problems: For example, pluripotent cells can form germ line tumors, so-called teratomas.
Another possibility is not to completely turn back the course of development. For the first time, Trumpp’s team has succeeded in reprogramming mature human cells in such a way that a defined type of induced neural stem cells is produced that can multiply almost indefinitely. “We used four genetic factors like Yamanaka, but different ones for our reprogramming,” explains Marc Christian Thier, first author of the study. “We assumed that our factors would allow reprogramming to an early stage of development of the nervous system.”
In the past, other research groups also reprogrammed connective tissue cells into mature nerve cells or neural precursor cells. However, these artificially produced nerve cells often could not be expanded and could therefore hardly be used for therapeutic purposes. “Often, it was a heterogeneous mixture of different cell types that might not exist in the body under physiological conditions,” said Andreas Trumpp explaining the problems.
Together with stem cell researcher Frank Edenhofer from the University of Innsbruck and neuroscientist Hannah Monyer from DKFZ and the Heidelberg University Hospital, Trumpp and his team have succeeded in reprogramming different human cells: connective tissue cells of the skin or pancreas as well as peripheral blood cells. “The origin of the cells had no influence on the properties of the stem cells,” said Thier. In particular, the possibility of extracting neural stem cells from the blood of patients without invasive intervention is a decisive advantage for future therapeutic approaches.
What is special about the reprogrammed cells of the Heidelberg researchers is that they are a homogeneous cell type that resembles a stage of neural stem cells that occurs during the embryonic development of the nervous system. “Corresponding cells exist in mice and probably also in humans during early embryonic brain development,” said Thier. “We have described here a new neural stem cell type in the mammalian embryo.
These so called “induced Neural Plate Border Stem Cells” (iNBSCs) have a broad development potential. The iNBSCs of the Heidelberg scientists are expandable and multipotent and can develop in two different directions. On the one hand, they can take the path of development to mature nerve cells and their supplier cells, the glial cells, i.e. become cells of the central nervous system. On the other hand, they can also develop into cells of the neural crest, from which different cell types emerge, for example peripheral sensitive nerve cells or cartilage and bones of the skull.
The iNBSCs thus form an ideal basis for generating a broad range of different cell types for an individual patient. “These cells have the same genetic material as the donor and are therefore presumably recognized as “self” by the immune system and are not rejected,” explains Thier.
The CRISPR/Cas9 gene scissors can be used to modify the iNBSC or repair genetic defects, as the scientists have shown in their experiments. “They are therefore of interesting both for basic research and the search for new active substances and for the development of regenerative therapies, for example in patients with diseases of the nervous system. However until we can use them in patients, a lot of research work will still be necessary,” emphasizes Trumpp.
The Latest on: Regenerative medicine
via Google News
The Latest on: Regenerative medicine
- June 2021 Report on Global Regenerative Medicine Partnering Terms and Agreements Market Size, Share, Value, and Competitive Landscape 2020on June 11, 2021 at 10:53 pm
The Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding ...
- Breakthrough Understanding of Limb and Organ Regeneration – Closer to the Development of Regenerative Medicine Therapieson June 11, 2021 at 11:54 am
Discovery in Salamanders by James W. Godwin, Ph.D., brings science closer to the development of regenerative medicine therapies. Many salamanders can readily regenerate a lost limb, but adult mammals, ...
- ISS National Lab to Host Session at World Stem Cell Summit on Regenerative Medicine in Low Earth Orbiton June 11, 2021 at 9:11 am
ISS National Lab to Host Session at World Stem Cell Summit on Regenerative Medicine in Low Earth Orbit. Press Release From: Center for the Advancement of Science in Space (CASIS) ...
- Regenerative Medicine Market Size, Major Manufacturers, Production and Market Comparison Analysis up to 2025on June 11, 2021 at 1:20 am
Request a sample Report of Regenerative Medicine Market Analysis Report at: Global Regenerative Medicine Market Analysis, 2020 research report depicts a deep dive market analysis of statistics of ...
- Regenerative Medicine Market 2021 Analysis and Leading Competitors – Vericel, Gilead Sciences, Novartis, Spark Therapeuticson June 9, 2021 at 6:44 am
The Regenerative Medicine Market is expected to grow at a CAGR of 8.27% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary ...
- iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Teamon June 9, 2021 at 6:28 am
Company advancing regenerative cell therapy platform technology with broad utility toward first-in-man study Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering ...
- National Center for Regenerative Medicine expands institutional membershipon June 9, 2021 at 4:27 am
MetroHealth System joins Case Western Reserve University, Cleveland Clinic and University Hospitals partnership The National Center for ...
- Restoring Vision To The Blind. Regenerative Medicine Offers New Hope For Retinitis Pigmentosaon June 8, 2021 at 7:57 am
Imagine gradually losing your vision over the course of forty years, waking up every morning with a tiny bit more of your peripheral vision grayed out, until you succumb to complete blindness as more ...
- Essent Biologics Launches Human Mesenchymal Stem Cells For Regenerative Medicine, Biopharmaceutical And Cell Therapy Researchon June 8, 2021 at 4:27 am
Essent Biologics™, a nonprofit biotechnology company setting a new standard in human-derived biomaterials and comprehensive data for research, today announced the launch of its human mesenchymal stem ...
- The regenerative medicine market size to grow at a CAGR of around 30% during the period 2020-2026on June 3, 2021 at 10:05 pm
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Regenerative Medicine Market Report. The regenerative medicine market size to grow at a CAGR of around 34% ...
via Bing News